COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae Registry
Study Details
Study Description
Brief Summary
COLUMBIA CARDS is a pilot study to understand how COVID-19 affects the heart. It is known that COVID-19 can affect the heart in different ways. COLUMBIA CARDS is studying why some COVID-19 survivors develop clinical conditions such as heart inflammation, fluid buildup, blood clots, and other cardiac problems during or after their COVID-19 illness, and why other ones do not. In this study, we will use cardiovascular magnetic resonance (CMR) and transthoracic echocardiography (TTE) to better understand the impact of COVID-19 on the heart.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This is a pilot study aiming to collect preliminary data on cardiac imaging (CMR and TTE) in outpatients who recovered from COVID-19.
CMR offers the unique ability to comprehensively characterize myocardial tissue and assess the heart's structure and function, through a variety of complementary imaging techniques using different pulse sequences. The investigators propose to provide a multi-sequence CMR evaluation of a spectrum of convalescent COVID-19 patients, compare COVID-19 survivors to controls, and study the relationships between myocardial characteristics by CMR and echocardiography and health outcomes, and how these are modulated through patient characteristics, and clinical characteristics of COVID-19 illness. Broadly, this myocardial characterization will not just provide diagnosis but serve as a potentially powerful tool for risk stratification, therapeutic decision making, and monitoring response to therapies in COVID-19 survivors.
Transthoracic echocardiography (TTE) is the most widely used imaging technique for the assessment of cardiac morphology and function. While its capability for myocardial tissue characterization is inferior to that of CMR, TTE provides several advantages that make it an ideal complement to CMR for the assessment of cardiac involvement in COVID-19 patients. TTE offers a rapid noninvasive evaluation of myocardial and valvular function, in addition to the assessment of other cardiac abnormalities of interest (such as presence and amount of pericardial effusion) and important hemodynamic variables (noninvasive estimation of pulmonary pressures is an example). TTE is easily performed and reproducible, and does not involve the use of radiations or contrast agents, which allows the performance of repeat evaluations to assess serial changes over time in the cardiac parameters of interest.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| COVID-19 Non-prisoner and non-pregnant subjects, without prior cardiac disease, who have tested positive or have been hospitalized due to COVID-19 infection. Subjects will be undergo a physical exam, blood draw to asses serological biomarkers. Subjects will also undergo an transthoracic echocardiogram (TTE) and a clariscan-enhanced cardiovascular magnetic resonance imaging (CMR) using a gadolinium based contrast agent (GBCA). |
Other: Transthoracic echocardiogram (TTE)
Subjects will undergo TTE imaging.
Other: Cardiovascular Magnetic Resonance (CMR) Imaging
Subjects will undergo CMR Imaging using a gadolinium based contrast agent (GBCA).
|
| Control Non-prisoner and non-pregnant subjects, without prior cardiac disease, who have never tested positive and/or has never been hospitalized due to COVID-19 infection. Subjects will be undergo a physical exam, blood draw to asses serological biomarkers. Subjects will also undergo an transthoracic echocardiogram (TTE) and a clariscan-enhanced cardiovascular magnetic resonance imaging (CMR) using a gadolinium based contrast agent (GBCA). |
Other: Transthoracic echocardiogram (TTE)
Subjects will undergo TTE imaging.
Other: Cardiovascular Magnetic Resonance (CMR) Imaging
Subjects will undergo CMR Imaging using a gadolinium based contrast agent (GBCA).
|
Outcome Measures
Primary Outcome Measures
- Percentage of myocardium demonstrating late gadolinium enhancement [Up to 2 hours]
Percentage of myocardium demonstrating late gadolinium enhancement by cardiac magnetic resonance (CMR) imaging, determined using Circle cvi42 software.
- Extracellular Volume (ECV) Fraction [Up to 2 hours]
Extracellular volume fraction measured by CMR imaging. ECV determined using Circle cvi42 software and using formula ECV = (1-hematocrit) × (Δ(1/T1myocardium)/Δ(1/T1blood)).
- Left Ventricular Ejection Fraction [Up to 2 hours]
Left ventricular ejection fraction (percent ejection fraction) by CMR imaging and determined using Circle cvi42 software.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Convalescent COVID-19 patient
-
If COVID-19 patient, at least 4 weeks after beginning of symptoms, and at least 2 weeks after hospital discharge if had been hospitalized.
-
Control patients who have had a negative COVID-19 screening without prior positive tests.
-
Willingness to undergo Clariscan-enhanced CMR scan.
-
Ability to hold breath for 15 seconds.
-
Willingness to give informed consent.
-
Greater than or equal to 18 years of Age.
Exclusion Criteria:
-
Subjects who are Pregnant or nursing
-
Severe valvular heart disease
-
History of congestive heart failure preceding COVID-19
-
History of obstructive coronary artery disease with known stenosis >70% or fractional flow reserve < 0.8
-
Contraindication to MRI
-
Known allergy to gadoterate
-
Estimated glomerular filtration rate <30 ml/min/1.73m2
-
History of receiving more than 2 doses of a gadolinium-based contrast agent
-
Subject is of prisoner status
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Columbia University Irving Medical Center | New York | New York | United States | 10032 |
Sponsors and Collaborators
- Columbia University
- GE Healthcare
Investigators
- Principal Investigator: Andrew J. Einstein, MD, PhD, Columbia Univeristy
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AAAT0787